CDMO

Scinai leadership to attend BIO-Europe Spring 2024

Retrieved on: 
Tuesday, March 12, 2024
Partnership, Inflammation, CDMO, I&I

JERUSALEM, March 12, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that it will be participating in partnership meetings and exhibiting its CDMO services at the BIO-Europe Spring 2024 conference, taking place March 18 to 20 in Barcelona.

Key Points: 
  • JERUSALEM, March 12, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that it will be participating in partnership meetings and exhibiting its CDMO services at the BIO-Europe Spring 2024 conference, taking place March 18 to 20 in Barcelona.
  • Several members of Scinai's leadership team will be available for discussions with:
    Prospective clients of the company's end-to-end biologics CDMO services.
  • All interested parties are encouraged to schedule a meeting through the conference partnering platform or to email Scinai at [email protected] to schedule a meeting.
  • Throughout the conference, Scinai will also be available at exhibitor booth #119 to showcase its CDMO services.

Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy

Retrieved on: 
Tuesday, March 12, 2024
GPCR, CLD, CDMO, Organization, Partnership, Patient, CGMP, Research, Cutaneous T-cell lymphoma, Cancer, G protein-coupled receptor, CTCL, Gq alpha subunit, Therapy, CCR8, Vaccine

Under the terms of the agreement, Chime Biologics will ensure stable cell line development (CLD) and DT-7012 candidate manufacturing to support clinical trials in strategic countries.

Key Points: 
  • Under the terms of the agreement, Chime Biologics will ensure stable cell line development (CLD) and DT-7012 candidate manufacturing to support clinical trials in strategic countries.
  • Chime Biologics' first global modular facility with single-use bioprocessing technology meets international cGMP standards with proven audit track records.
  • Stephan Schann, Chief Scientific Officer of Domain Therapeutics, said: "We're thrilled to collaborate with Chime Biologics, a great scientific and manufacturing expert, to advance DT-7012, our leading anti-CCR8 candidate, to the next development stage.
  • At Domain, we prioritize precision research and innovation and embrace new partnerships with organizations that share our vision and passion to advance immuno-oncology".

MIKART ANNOUNCES VALIDATION OF ITS NEW LIQUID AND SUSPENSION SUITE

Retrieved on: 
Monday, March 11, 2024
CDMO, Patient, Liquid, The central science, Safety, Health, Pharmaceutical industry

ATLANTA, March 8, 2024 /PRNewswire/ -- Mikart LLC, a leading contract development and manufacturing company, proudly announces the successful validation of its liquid product within its innovative Liquid and Suspension Suite for an Oral Solution Program.

Key Points: 
  • ATLANTA, March 8, 2024 /PRNewswire/ -- Mikart LLC, a leading contract development and manufacturing company, proudly announces the successful validation of its liquid product within its innovative Liquid and Suspension Suite for an Oral Solution Program.
  • The validation of the first product within the Liquid and Suspension Suite underscores Mikart dedication to providing reliable and effective pharmaceutical solutions.
  • "We are thrilled to announce the validation of our inaugural product in our new Liquid and Suspension Suite," said Michael Kallelis, CEO at Mikart.
  • Nazar Elkarim, Vice President of Product Development Services at Mikart, added, "The successful validation of our first product in the new liquid and suspension suite is a testament of our team's dedication and expertise in product development.

EQS-News: Rentschler Biopharma contributes to nearly 25% of FDA approved biopharmaceuticals in 2023

Retrieved on: 
Wednesday, March 13, 2024
Therapy, Senior, Caregiver, DCAT, SVP, FDA, Technology transfer, Food, Business development, CDMO, CDER, Monoclonal antibody, Patient, Cancer

Laupheim, Germany, Milford (MA), USA, and Stevenage, UK, March 6, 2024 – In 2023, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 55 new drugs, 17 of which were biopharmaceuticals.

Key Points: 
  • Laupheim, Germany, Milford (MA), USA, and Stevenage, UK, March 6, 2024 – In 2023, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 55 new drugs, 17 of which were biopharmaceuticals.
  • Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), contributed to four, which equals nearly 25%, of these biopharmaceuticals.
  • For the four newly approved products, Rentschler Biopharma provided support with integrated capabilities, including consulting, regulatory services, process development, technology transfer and manufacturing.
  • Benedikt von Braunmühl, CEO of Rentschler Biopharma, said: “At Rentschler Biopharma, we strive to create value sustainably, together with our client partners, for patients with serious and rare diseases worldwide.

BioHarvest Sciences Signs First Contracts with Two Industrial Customers to Develop Complex Molecules via Its Newly Launched Botanical Synthesis CDMO Business Unit

Retrieved on: 
Monday, February 26, 2024
Steps, Biotechnology, Food, Confidentiality, Plant, Biomass, NRE, Entrepreneurship, CDMO, Step, Safety, BHSC, Rehovot, Fine chemical

The new business unit allows pharmaceutical, cosmeceutical, nutraceutical and nutrition industry leaders the opportunity to partner with BioHarvest to utilize its Botanical Synthesis Process technology through a typical CDMO contracting model.

Key Points: 
  • The new business unit allows pharmaceutical, cosmeceutical, nutraceutical and nutrition industry leaders the opportunity to partner with BioHarvest to utilize its Botanical Synthesis Process technology through a typical CDMO contracting model.
  • This proprietary process technology enables the development and manufacturing of patentable plant based small molecules, complex molecules, and unique compositions which include both small and complex molecules.
  • As a result of these advantages, the Company has decided to call these unique plant-derived complex molecules BIOLOGICS+.
  • The CDMO business offers the Botanical Synthesis process technology in 3 major steps to its customers.

Avid Bioservices (CDMO) Tanks 30% After Disclosing Possible Accounting Restatements Due to $146 Million Acceleration Notice – Hagens Berman

Retrieved on: 
Monday, March 11, 2024
CDMO, SAN, Hagens Berman, Sale, Classification, Person, Failure, Note, Pharmaceutical industry

SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Avid Bioservices, Inc. (NASDAQ: CDMO) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Avid Bioservices, Inc. (NASDAQ: CDMO) investors who suffered substantial losses to submit your losses now .
  • 2021, Avid privately placed $143.8 million of 1.250% exchangeable senior notes due 2026 (“2026 Notes”) with qualified institutional investors.
  • In addition, the indenture governing the 2026 Notes required Avid to remove the legend by March 17, 2022.
  • Avid said it would use the proceeds from the new convertible notes to pay down the 1.250% exchangeable senior notes.

FUJIFILM Diosynth Biotechnologies Appoints Richard McAvoy as Chief Financial Officer

Retrieved on: 
Monday, March 11, 2024
CFO, Head, Potyvirus, Life, Growth, Novo Nordisk, Alston & Bird, Vaccine, CDMO, History, Financial management, Small Business Saturday, Partner, Fujifilm Diosynth Biotechnologies, Management

In his new role, McAvoy will be responsible for the Company’s financial strategies, overseeing all financial activities within the organization, ensuring robust financial management and contributing to the realization of FUJFILM Diosynth Biotechnologies’ aggressive growth strategy.

Key Points: 
  • In his new role, McAvoy will be responsible for the Company’s financial strategies, overseeing all financial activities within the organization, ensuring robust financial management and contributing to the realization of FUJFILM Diosynth Biotechnologies’ aggressive growth strategy.
  • We look forward to Richard’s contributions as we execute on our growth strategy," said Lars Petersen, president and chief executive officer of FUJIFILM Diosynth Biotechnologies.
  • Prior to joining FUJIFILM Diosynth Biotechnologies, he held leadership roles at Novo Nordisk and Alston & Bird LLP.
  • To find more information on all members of the FUJIFILM Diosynth Biotechnologies Executive Leadership team please visit: www.fujifilmdiosynth.com/leadership

INVESTIGATION UPDATE: Halper Sadeh LLC Investigates CHRD, AA, NGM, SCTL

Retrieved on: 
Saturday, March 9, 2024
NGM, Enerplus, LP, Alumina Limited, Society, Fraud, Sale, Advertising, CDMO, Column, Security (finance)

If you are a Chord shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Chord shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Scorpius Holdings, Inc. Announces Pricing of Public Offering

Retrieved on: 
Friday, March 8, 2024
ThinkEquity, Prospectus, Sale, Form, CDMO, State Street, S-3, Life insurance

DURHAM, N.C., March 08, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $0.15 per share, for aggregate gross proceeds of $1,500,000, before deducting underwriting discounts, commissions and offering expenses.

Key Points: 
  • DURHAM, N.C., March 08, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $0.15 per share, for aggregate gross proceeds of $1,500,000, before deducting underwriting discounts, commissions and offering expenses.
  • The offering is expected to close on March 12, 2024, subject to satisfaction of customary closing conditions.
  • The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes.
  • A preliminary prospectus supplement and the accompanying base prospectus describing the terms of the offering was filed with the SEC on its website at www.sec.gov.

AVID ALERT: Bragar Eagel & Squire, P.C. is Investigating Avid Bioservices, Inc. on Behalf of Avid Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 8, 2024
CDMO, Telephone, Bank statement, P.C

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Avid Bioservices, Inc. (“Avid” or the “Company”) (NASDAQ: CDMO) on behalf of Avid stockholders.

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Avid Bioservices, Inc. (“Avid” or the “Company”) (NASDAQ: CDMO) on behalf of Avid stockholders.
  • Our investigation concerns whether Avid has violated the federal securities laws and/or engaged in other unlawful business practices.
  • Avid attributed this to having failed to remove a restrictive legend on previously issued 1.25% exchangeable notes.
  • Shares of Avid Bioservices, Inc. dropped more than 28% in intraday trading on March 7, 2024.